BLEND LABS INC-A (BLND) Fundamental Analysis & Valuation

NYSE:BLND • US09352U1088

Current stock price

1.7 USD
-0.05 (-2.86%)
At close:
1.7 USD
0 (0%)
After Hours:

This BLND fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. BLND Profitability Analysis

1.1 Basic Checks

  • BLND had positive earnings in the past year.
  • BLND had a positive operating cash flow in the past year.
  • In the past 5 years BLND always reported negative net income.
  • BLND had negative operating cash flow in 4 of the past 5 years.
BLND Yearly Net Income VS EBIT VS OCF VS FCFBLND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 -200M -400M -600M

1.2 Ratios

  • The Return On Assets of BLND (-14.71%) is worse than 69.78% of its industry peers.
  • BLND's Return On Equity of -19.40% is in line compared to the rest of the industry. BLND outperforms 40.65% of its industry peers.
Industry RankSector Rank
ROA -14.71%
ROE -19.4%
ROIC N/A
ROA(3y)-46.39%
ROA(5y)-66.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BLND Yearly ROA, ROE, ROICBLND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 500 -500

1.3 Margins

  • BLND's Gross Margin of 73.84% is fine compared to the rest of the industry. BLND outperforms 61.15% of its industry peers.
  • In the last couple of years the Gross Margin of BLND has grown nicely.
  • The Profit Margin and Operating Margin are not available for BLND so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.84%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y24.59%
GM growth 5Y2.79%
BLND Yearly Profit, Operating, Gross MarginsBLND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. BLND Health Analysis

2.1 Basic Checks

  • BLND does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • BLND has less shares outstanding than it did 1 year ago.
  • BLND has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for BLND. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BLND Yearly Shares OutstandingBLND Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
BLND Yearly Total Debt VS Total AssetsBLND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • BLND has an Altman-Z score of -4.17. This is a bad value and indicates that BLND is not financially healthy and even has some risk of bankruptcy.
  • BLND has a Altman-Z score of -4.17. This is amonst the worse of the industry: BLND underperforms 81.65% of its industry peers.
  • BLND has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.17
ROIC/WACCN/A
WACC10.92%
BLND Yearly LT Debt VS Equity VS FCFBLND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • BLND has a Current Ratio of 2.48. This indicates that BLND is financially healthy and has no problem in meeting its short term obligations.
  • BLND has a better Current ratio (2.48) than 67.63% of its industry peers.
  • A Quick Ratio of 2.48 indicates that BLND has no problem at all paying its short term obligations.
  • BLND has a better Quick ratio (2.48) than 68.35% of its industry peers.
Industry RankSector Rank
Current Ratio 2.48
Quick Ratio 2.48
BLND Yearly Current Assets VS Current LiabilitesBLND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. BLND Growth Analysis

3.1 Past

  • BLND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 112.50%, which is quite impressive.
  • The Revenue for BLND has decreased by -23.76% in the past year. This is quite bad
  • BLND shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.17% yearly.
EPS 1Y (TTM)112.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.7%
Revenue 1Y (TTM)-23.76%
Revenue growth 3Y-19.32%
Revenue growth 5Y5.17%
Sales Q2Q%-21.83%

3.2 Future

  • Based on estimates for the next years, BLND will show a very strong growth in Earnings Per Share. The EPS will grow by 282.98% on average per year.
  • The Revenue is expected to grow by 13.41% on average over the next years. This is quite good.
EPS Next Y692.23%
EPS Next 2Y282.98%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year15.22%
Revenue Next 2Y15.52%
Revenue Next 3Y13.41%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BLND Yearly Revenue VS EstimatesBLND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M
BLND Yearly EPS VS EstimatesBLND Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

3

4. BLND Valuation Analysis

4.1 Price/Earnings Ratio

  • BLND is valuated quite expensively with a Price/Earnings ratio of 170.00.
  • The rest of the industry has a similar Price/Earnings ratio as BLND.
  • The average S&P500 Price/Earnings ratio is at 25.23. BLND is valued rather expensively when compared to this.
  • The Price/Forward Earnings ratio is 21.46, which indicates a rather expensive current valuation of BLND.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of BLND indicates a somewhat cheap valuation: BLND is cheaper than 60.07% of the companies listed in the same industry.
  • BLND is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.51, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 170
Fwd PE 21.46
BLND Price Earnings VS Forward Price EarningsBLND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLND Per share dataBLND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3 0.4 0.5

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as BLND's earnings are expected to grow with 282.98% in the coming years.
PEG (NY)0.25
PEG (5Y)N/A
EPS Next 2Y282.98%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BLND Dividend Analysis

5.1 Amount

  • BLND does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BLND Fundamentals: All Metrics, Ratios and Statistics

BLEND LABS INC-A

NYSE:BLND (3/26/2026, 8:06:29 PM)

After market: 1.7 0 (0%)

1.7

-0.05 (-2.86%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)03-10
Earnings (Next)N/A
Inst Owners77.86%
Inst Owner Change5.58%
Ins Owners4.02%
Ins Owner Change5.32%
Market Cap435.27M
Revenue(TTM)123.52M
Net Income(TTM)-25.01M
Analysts80
Price Target4.29 (152.35%)
Short Float %6.41%
Short Ratio4.2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-100%
Min EPS beat(2)-100%
Max EPS beat(2)-100%
EPS beat(4)1
Avg EPS beat(4)-19.36%
Min EPS beat(4)-100%
Max EPS beat(4)222.55%
EPS beat(8)4
Avg EPS beat(8)-0.28%
EPS beat(12)7
Avg EPS beat(12)4.17%
EPS beat(16)9
Avg EPS beat(16)1.12%
Revenue beat(2)0
Avg Revenue beat(2)-0.95%
Min Revenue beat(2)-1.77%
Max Revenue beat(2)-0.14%
Revenue beat(4)0
Avg Revenue beat(4)-8.95%
Min Revenue beat(4)-30.67%
Max Revenue beat(4)-0.14%
Revenue beat(8)2
Avg Revenue beat(8)-3.88%
Revenue beat(12)4
Avg Revenue beat(12)-1.7%
Revenue beat(16)7
Avg Revenue beat(16)-0.08%
PT rev (1m)0%
PT rev (3m)-9.95%
EPS NQ rev (1m)-42.5%
EPS NQ rev (3m)-42.5%
EPS NY rev (1m)0%
EPS NY rev (3m)-10.93%
Revenue NQ rev (1m)-4.14%
Revenue NQ rev (3m)-4.14%
Revenue NY rev (1m)-3.83%
Revenue NY rev (3m)-3.83%
Valuation
Industry RankSector Rank
PE 170
Fwd PE 21.46
P/S 3.52
P/FCF N/A
P/OCF 37.81
P/B 3.38
P/tB 3.38
EV/EBITDA N/A
EPS(TTM)0.01
EY0.59%
EPS(NY)0.08
Fwd EY4.66%
FCF(TTM)0
FCFYN/A
OCF(TTM)0.04
OCFY2.64%
SpS0.48
BVpS0.5
TBVpS0.5
PEG (NY)0.25
PEG (5Y)N/A
Graham Number0.34
Profitability
Industry RankSector Rank
ROA -14.71%
ROE -19.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.84%
FCFM N/A
ROA(3y)-46.39%
ROA(5y)-66.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y24.59%
GM growth 5Y2.79%
F-Score6
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 352.59%
Cap/Sales 9.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.48
Quick Ratio 2.48
Altman-Z -4.17
F-Score6
WACC10.92%
ROIC/WACCN/A
Cap/Depr(3y)268.82%
Cap/Depr(5y)168.4%
Cap/Sales(3y)6.09%
Cap/Sales(5y)3.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)112.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.7%
EPS Next Y692.23%
EPS Next 2Y282.98%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-23.76%
Revenue growth 3Y-19.32%
Revenue growth 5Y5.17%
Sales Q2Q%-21.83%
Revenue Next Year15.22%
Revenue Next 2Y15.52%
Revenue Next 3Y13.41%
Revenue Next 5YN/A
EBIT growth 1Y52.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year133.25%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y99.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y188.26%
OCF growth 3YN/A
OCF growth 5YN/A

BLEND LABS INC-A / BLND Fundamental Analysis FAQ

What is the fundamental rating for BLND stock?

ChartMill assigns a fundamental rating of 4 / 10 to BLND.


What is the valuation status of BLEND LABS INC-A (BLND) stock?

ChartMill assigns a valuation rating of 3 / 10 to BLEND LABS INC-A (BLND). This can be considered as Overvalued.


How profitable is BLEND LABS INC-A (BLND) stock?

BLEND LABS INC-A (BLND) has a profitability rating of 2 / 10.


How financially healthy is BLEND LABS INC-A?

The financial health rating of BLEND LABS INC-A (BLND) is 7 / 10.